The Power of Truth^® has been released for sale and assignment to a conservative pro-American news outlet, cable network, or other media outlet that wants to define and brand its operation as the bearer of the truth, and set itself above the competition.

In every news story the audience hears of censorship, speech, and the truth. The Power of Truth^® has significant value to define an outlet, and expand its audience. A growing media outlet may decide to rebrand their operation The Power of Truth^®. An established outlet may choose to make it the slogan distinguishing their operation from the competition. You want people to think of your outlet when they hear it, and think of the slogan when they see your company name. It is the thing which answers the consumer's questions: Why should I choose you? Why should I listen to you? Think:

What’s in your wallet -- Capital One
The most trusted name in news – CNN
Fair and balanced - Fox News
Where’s the beef -- Wendy’s
You’re in good hands -- Allstate
The ultimate driving machine -- BMW

The Power of Truth^® is registered at the federal trademark level in all applicable trademark classes, and the sale and assignment includes the applicable domain names. The buyer will have both the trademark and the domains so that it will control its business landscape without downrange interference.

Contact: Truth@ThePowerOfTruth.com

Sidebar

Magazine menu

The Power of Truth^®

Monday, December 23, 2024

Encouraging Phase 1 data for glioblastoma treatment

Health

Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio's genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.

Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio's genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.

HUNGRY FOR TRUTH? FEED THE NEED.